Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) is now available.
Shanghai Pharmaceuticals Holding Co., Ltd. announced the renewal of its Procurement Framework Agreement with Wing Fat Printing, effective from January 1, 2026, to December 31, 2026. This agreement allows Wing Fat Group to continue supplying printed packaging materials for pharmaceutical products, ensuring the stability of Shanghai Pharmaceuticals’ operations and meeting future demand. The transactions are classified as continuing connected transactions under the Listing Rules, subject to specific reporting and review requirements but exempt from circular and independent shareholders’ approval. The annual cap for these transactions is set at RMB90,000,000, based on estimated future demand and historical procurement amounts. The agreement is expected to benefit the company by reducing administrative costs and maintaining business stability.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.50 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. is a major player in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products. The company is known for its comprehensive range of pharmaceutical services and products, catering to a broad market segment within the healthcare sector.
Average Trading Volume: 3,259,649
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$77.57B
Learn more about 2607 stock on TipRanks’ Stock Analysis page.